McKesson Corporation (MCK)
$
686.64
+5.62 (0.82%)
Key metrics
Financial statements
Free cash flow per share
45.9888
Market cap
85.4 Billion
Price to sales ratio
0.2262
Debt to equity
-5.0498
Current ratio
0.8829
Income quality
1.9809
Average inventory
24 Billion
ROE
-1.2479
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
McKesson Corporation, founded in 1833 and headquartered in Irving, Texas, provides a wide range of healthcare services both in the United States and internationally. The company operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment is involved in the distribution of branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, along with other healthcare-related products. Additionally, this segment offers practice management, technology, clinical support, and business solutions tailored for community-based oncology and other specialty practices. It also provides consulting, outsourcing, technological, and various services while selling financial, operational, and clinical solutions to pharmacies. The International segment serves wholesale, institutional, and retail customers across 13 European countries and Canada. The Medical-Surgical Solutions segment focuses on distributing medical-surgical supplies, logistics, and other essential services to healthcare providers. Meanwhile, the RxTS segment caters to biopharma and life sciences partners, addressing medication challenges throughout patient journeys; it connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions while also providing third-party logistics and wholesale distribution support solutions. The company reported depreciation and amortization expenses of $636,000,000.00 reflecting the wear and tear of its assets. Its selling, general, and administrative expenses total $8,022,000,000.00 indicating operational overhead costs. The interest income earned amounting to $173,000,000.00 showcases its financial investments. Overall, the total costs and expenses for the company are $354,679,000,000.00 reflecting comprehensive spending, while the EBITDA stands at $5,251,000,000.00 a key indicator of the company's operational profitability. In the financial marketplace, the stock is priced at $715.57 positioning it in the higher-end market. It has an average trading volume of 777,068.00 indicating moderate liquidity in its trading activities. With a significant market capitalization of $85,407,029,760.00 McKesson Corporation establishes itself as a dominant player in the healthcare industry. The company is an essential participant in the Medical - Distribution industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its domain.
Investing in McKesson Corporation (MCK) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict McKesson Corporation stock to fluctuate between $464.42 (low) and $737.89 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-08-29, McKesson Corporation's market cap is $85,407,029,760, based on 124,384,000 outstanding shares.
Compared to Eli Lilly & Co., McKesson Corporation has a Lower Market-Cap, indicating a difference in performance.
McKesson Corporation pays dividends. The current dividend yield is 0.43%, with a payout of $0.82 per share.
To buy McKesson Corporation (MCK) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for MCK. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
McKesson Corporation's last stock split was 2:1 on 1998-01-05.
Revenue: $359,051,000,000 | EPS: $25.86 | Growth: 14.73%.
Visit https://www.mckesson.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $737.89 (2025-07-08) | All-time low: $192.38 (2021-08-10).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
McKesson beats on Q1 earnings and raises FY26 EPS view, but shares slip as gross margin narrows and spin-off plans weigh on investors' sentiment.
seekingalpha.com
McKesson Corporation (NYSE:MCK ) Q1 2026 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Brian S. Tyler - CEO & Director Britt J.
zacks.com
McKesson (MCK) came out with quarterly earnings of $8.26 per share, beating the Zacks Consensus Estimate of $8.23 per share. This compares to earnings of $7.88 per share a year ago.
reuters.com
U.S. drug distributor McKesson raised its annual profit forecast and beat Wall Street earnings estimates on Wednesday, banking on robust demand for specialty medicines.
zacks.com
McKesson (MCK) reached $693.54 at the closing of the latest trading day, reflecting a -2.99% change compared to its last close.
zacks.com
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
zacks.com
Here is how McKesson (MCK) and Cencora (COR) have performed compared to their sector so far this year.
seekingalpha.com
McKesson delivered strong double-digit growth in revenue, earnings, and free cash flow in fiscal 2025, outperforming the S&P 500 significantly. The planned spin-off of the underperforming Medical-Surgical Solutions segment will sharpen McKesson's focus on higher-growth, higher-margin oncology and biopharma businesses. Management and analysts expect continued double-digit earnings growth, supported by robust share buybacks and optimistic long-term guidance.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
See all news